p.97 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e368

CLINICAL STATEMENTS AND GUIDELINES S7.2.1-9.	 Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in

advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol. 1993;21:110–6. S7.2.1-10.	Olshansky B, Poole JE, Johnson G, et al. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. J Am Coll Cardiol. 2008;51:1277–82. S7.2.1-11.	Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk cardiomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) study. Circulation. 2014;129:545–52. S7.2.1-12.	Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245–53. S7.2.1-13.	Claro JC, Candia R, Rada G, et al. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015;12:CD008093. S7.2.1-14.	Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009;32:755–61. S7.2.1-15.	Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2013;6:504–12. S7.2.1-16.	Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electrophysiological studies to predict arrhythmic events. World J Cardiol. 2015;7:344–50. S7.2.1-17.	Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use

after acute myocardial infarction complicated by heart failure and/ or left ventricular dysfunction may be associated with excess mortality. Am Heart J. 2008;155:87–93.

7.2.2 Primary Prevention of SCD in Patients With NICM

S7.2.2-1.	 Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37. S7.2.2-2.	 Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453–8. S7.2.2-3.	 Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50. S7.2.2-4.	 Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874–9. S7.2.2-5.	 Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–8. S7.2.2-6.	 Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol. 2003;41:1707–12. S7.2.2-7.	 Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverterdefibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492–8. S7.2.2-8.	 Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250–60. S7.2.2-9.	 Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79–83. S7.2.2-10.	van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59: 493–500. S7.2.2-11.	Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in

patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–30. S7.2.2-12.	Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention

implantable cardioverter defibillators in patients with nonischemic cardiomyopathy: a meta-analysis. JAMA Cardiol. 2017;2:685–8. S7.2.2-13.	Golwala H, Bajaj NS, Arora G, et al. Implantable cardioverter-defi-

brillator for nonischemic cardiomyopathy: an updated meta-analysis. Circulation. 2017;135:201–3.

7.2.3 Treatment of Recurrent VA in Patients With NICM

S7.2.3-1.	 Connolly SJ, Dorian P, Roberts RS, et al. Comparison of betablockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165–71. S7.2.3-2.	 Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129:728–36. S7.2.3-3.	 Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997–2007. S7.2.3-4.	 Piers SR, Tao Q, Tvan Huls van Taxis CF, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875–83. S7.2.3-5.	 Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2013;6:891–7. S7.2.3-6.	 Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment

approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407–13.

7.3 Arrhythmogenic Right Ventricular

Cardiomyopathy

S7.3-1.	Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015;8:437–46. S7.3-2.	Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013;61:1945–8. S7.3-3.	Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123:2701–9. S7.3-4.	te Riele AS, James CA, Groeneweg JA, et al. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016;37:755–63. S7.3-5.	Liu T, Pursnani A, Sharma UC, et al. Effect of the 2010 task force criteria on reclassification of cardiovascular magnetic resonance criteria for arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:47. S7.3-6.	Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–41. S7.3-7.	te Riele AS, Bhonsale A, James CA, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1761–9. S7.3-8.	Vermes E, Strohm O, Otmani A, et al. Impact of the revision of arrhythmogenic right ventricular cardiomyopathy/dysplasia task force criteria on its prevalence by CMR criteria. JACC Cardiovasc Imag. 2011;4:282–7. S7.3-9.	Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors

of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58:1485–96.

Downloaded from http://ahajournals.org by on October 7, 2026